Status:
COMPLETED
Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms
Lead Sponsor:
Thomas Hope
Conditions:
Intracranial Neoplasm
Low Grade Glioma
Eligibility:
All Genders
3+ years
Phase:
PHASE2
Brief Summary
This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back. FET accumulates in malignant...
Detailed Description
PRIMARY OBJECTIVES: I. To determine if F-18 fluoroethyltyrosine (FET) PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology in population 1 with rec...
Eligibility Criteria
Inclusion
- Age \> 3 years.
- Presence or suspicion of intracranial neoplasm in two populations.
- Population 1: Patients after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on magnetic resonance imaging (MRI). Three sub-populations will be considered:
- Recurrent metastatic lesions.
- Recurrent high-grade gliomas (grades 3 and 4).
- Recurrent low-grade gliomas (grades 1 and 2).
- Population 2: Patients prior to primary treatment with planned biopsy or surgical resection.
Exclusion
- Patient with known incompatibility to PET or computed tomography (CT)/MRI scans.
- Patient unlikely to comply with study procedures, restrictions and requirements and judged by the investigator to be unsuitable for study participation.
- Sedation or anesthesia can be used for patients who cannot tolerate the exam.
Key Trial Info
Start Date :
October 29 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2024
Estimated Enrollment :
143 Patients enrolled
Trial Details
Trial ID
NCT04044937
Start Date
October 29 2018
End Date
March 31 2024
Last Update
March 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94115